Onconic Therapeutics saw a significant simultaneous increase in both revenue and profit through the commercialization of its independently developed new drug.


On February 2, Onconic Therapeutics announced through a public disclosure that, due to a change of more than 30% in last year's revenue and profit structure, it recorded annual revenue of 53.4 billion won and operating profit of 12.6 billion won in the previous year.

Onconic Therapeutics Research Institute exterior. Onconic Therapeutics

Onconic Therapeutics Research Institute exterior. Onconic Therapeutics

View original image

Onconic Therapeutics' revenue last year reached approximately 53.4 billion won, a sharp increase of 259.8% compared to the previous year. Operating profit was about 12.6 billion won, turning around from an operating loss of 4.79779 billion won in the previous year. Net profit also returned to the black, recording 13.72422 billion won.


This performance reflects the sales growth of 'Zacubo', the 37th domestically developed new drug for gastroesophageal reflux disease, as well as milestone revenue from technology transfer to its Chinese partner Livzon, following the successful completion of phase 3 clinical trials and a marketing authorization application in China.


Since its launch in October 2024, Zacubo has been rapidly growing in the prescription market. According to out-of-hospital prescription data from UBIST, Zacubo’s monthly prescription sales expanded from about 500 million won in its first month of launch in October 2024 to about 6.6 billion won in December of the previous year, increasing by approximately 13 times in just over a year and establishing itself as a major product in the gastroesophageal reflux disease treatment market.


Onconic Therapeutics emphasized the significance of having established a business structure in which profits secured through the commercialization of its independently approved new drug are reinvested into subsequent new drug research and development. This demonstrates that the 'Gilead-style virtuous cycle of new drug R&D,' where actual profits generated from new drug approvals are used as funding for further research and development, is being realized in practice.


Based on this virtuous cycle, the company is accelerating the development of its next-generation anticancer drug pipeline. Its core anticancer pipeline, the next-generation synthetic lethal dual-target anticancer drug 'Nesuparib,' has entered phase 2 clinical trials for a total of four indications: pancreatic cancer, endometrial cancer, ovarian cancer, and gastric cancer, as the company actively speeds up clinical development of anticancer drugs. Nesuparib is being validated for its potential as a pan-tumor therapeutic new drug that is effective across multiple indications, not limited to specific cancer types.



A representative from Onconic Therapeutics stated, "Based on the late-stage clinical, CMC, and regulatory experience of Zacubo, which recorded sales of about 50 billion won in its first year, we have achieved a meaningful milestone by advancing our second new drug, Nesuparib, into phase 2 clinical trials for four indications." The representative added, "This year, we plan to maximize the value of Nesuparib by actively sharing its achievements at major domestic and international conferences."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing